FrancophonIA/ELRC3.0 huggingface dataset:
English: Uncommon (These may occur with up to 1 in 100 doses of the vaccine) :
Estonian: Aeg-ajalt (need võivad esineda kuni 1 vaktsiini annuse kohta 100-st):
English: Additional side effects that have been reported during clinical trials with very similar combined hepatitis A and hepatitis B vaccines, include:
Estonian: Kliinilistes uuringutes on kirjeldatud alljärgnevaid kõrvaltoimeid , mis on sarnased A-hepatiidi ja B-hepatiidi kombineeritud või eraldi vaktsiinide manustamisel.
English: NAME OF THE MEDICINAL PRODUCT Ambirix - Suspension for injection in pre-filled syringe Hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed)
Estonian: Hepatiit A (inaktiveeritud) ja hepatiit B (rDNA) vaktsiin (HAB), (adsorbeeritud)
English: NAME OF THE MEDICINAL PRODUCT Ambirix suspension for injection in pre-filled syringe Hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed).
Estonian: Hepatiit A (inaktiveeritud) ja hepatiit B (rDNA) vaktsiin (HAB), (adsorbeeritud).
English: • itching (pruritus), rash
Estonian: • kihelus, lööve
English: At 10 years following the initiation of a 0, 6 month schedule of Ambirix in children aged 1-15 years,
Estonian: 10ndal aastal pärast Ambirix'iga vaktsineerimise alustamist kuudel 0 ja 6 lastel vanuses 1…15 aastat säilis kõigil jälgitud isikutel anti-HAV antikehade tase ≥15 mIU/ml.
English: Rare (These may occur with up to 1 in 1,000 doses of the vaccine) :
Estonian: Harv (need võivad esineda kuni 1 vaktsiini annuse kohta 1000-st):
English: This is usually into the upper arm.
Estonian: Tavaliselt tehakse süst õlavarde.
English: • feeling drowsy
Estonian: • kõhulahtisus, iiveldus
English: Nervous system disorders Uncommon: dizziness Rare: paraesthesia
Estonian: Närvisüsteemi häired aeg-ajalt: pearinglus harv: paresteesia
English: Ambirix is indicated in non-immune children and adolescents from 1 year up to and including 15 years of age for protection against hepatitis A and hepatitis B infection.
Estonian: Ambirix on näidustatud A-hepatiidi ja B-hepatiidi vastaseks vaktsineerimiseks immuunsuseta 1...15 (k.a.)
English: Musculoskeletal and connective tissue disorders Uncommon: myalgia
Estonian: Ainevahetus- ja toitumishäired väga sage: isutus
English: What is Onzeald?
Estonian: Mis on Onzeald?
English: The company that applied for authorisation is Nektar Therapeutics UK Limited.
Estonian: Müügiluba taotles ettevõte Nektar Therapeutics UK Limited.
English: Irinotecan has been authorised in the EU for a number of years for the treatment of colorectal cancer.
Estonian: Irinotekaan on olnud Euroopa Liidus kolorektaalvähi raviks heaks kiidetud palju aastaid.
English: How does Onzeald work?
Estonian: Kuidas Onzeald toimib?
English: After considering the grounds for this request, the CHMP re-examined the opinion, and confirmed the refusal of the marketing authorisation on 9 November 2017.
Estonian: Pärast taotluse põhjenduste arutamist vaatas inimravimite komitee oma algse arvamuse uuesti läbi ja kinnitas müügiloa andmisest keeldumist 9. novembril 2017.
English: Refusal of the marketing authorisation for Onzeald (etirinotecan pegol) EMA/736863/2017
Estonian: Onzealdi (etirinotekaanpegool) müügiloa andmisest keeldumine EMA/736863/2017
English: The company informed the CHMP that patients receiving the medicine in clinical trials will continue to do so as planned.
Estonian: Ettevõte teatas inimravimite komiteele, et kliinilistes uuringutes ravimit saavad patsiendid kasutavad seda plaani kohaselt edasi.
English: On 20 July 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Onzeald, intended for the treatment of advanced breast cancer that has spread to the brain.
Estonian: 20. juulil 2017 võttis inimravimite komitee vastu negatiivse arvamuse, soovitades keelduda andmast ravimi Onzeald müügiluba, mida kavatseti kasutada peaajju levinud kaugelearenenud rinnavähi raviks.
English: Therefore, the CHMP was of the opinion that the study did not provide enough evidence on the benefits of Onzeald and recommended that the marketing authorisation be refused.
Estonian: Seetõttu oli inimravimite komitee seisukohal, et uuringuga ei esitatud Onzealdi kasulikkuse kohta piisavalt tõendeid, ning soovitas müügiloa andmisest keelduda.
English: In this study, Onzeald was compared with standard cancer medicines chosen by the treating doctor, and the main measure of effectiveness was overall survival (how long the patients lived).
Estonian: Uuringus võrreldi Onzealdi raviarsti valitud standardvähiravimitega; efektiivsuse põhinäitaja oli üldine elumus (kui kaua patsiendid elasid).
English: Onzeald is a cancer medicine that contains the active substance etirinotecan pegol.
Estonian: Onzeald on vähiravim, mis sisaldab toimeainena etirinotekaanpegooli.
English: The claim of effectiveness relied on data from a subgroup of patients from a main study which, overall, failed to convincingly show the effectiveness of Onzeald.
Estonian: Efektiivsuse väide põhines põhiuuringus osalenud patsientide alarühma andmetel ning kokkuvõttes ei suutnud need Onzealdi efektiivsust veenvalt tõendada.
English: By blocking the enzyme, cancer cells are prevented from multiplying and they eventually die.
Estonian: Ensüümi blokeerimine takistab vähirakkude paljunemist ja rakud seejärel hävivad.
English: Refusal of the marketing authorisation for Onzeald (etirinotecan pegol)
Estonian: Onzealdi (etirinotekaanpegool) müügiloa andmisest keeldumine
English: Irinotecan blocks topoisomerase I, an enzyme that is involved in copying cell DNA, which is needed to make new cells.
Estonian: Irinotekaan blokeerib ensüümi topoisomeraas I, mis osaleb raku DNA kopeerimises ja on seega vajalik uute rakkude loomiseks.
English: The Committee considered that the data from this subgroup, which were not supported by additional studies, were not sufficient to prove the effectiveness of Onzeald, even when analysed by different methods.
Estonian: Inimravimite komitee leidis, et alarühma andmed, mida lisauuringud ei toetanud, ei olnud isegi teistsuguste meetoditega analüüsides Onzealdi efektiivsuse tõendamiseks piisavad.
English: The company presented the results of one main study involving 852 patients with breast cancer that had spread to other parts of the body who had been treated with at least 2 other cancer medicines.
Estonian: Selles uuriti 852 patsienti, kelle rinnavähk oli levinud organismis ka mujale ja keda oli ravitud vähemalt kahe muu vähiravimiga.
English: The active substance in Onzeald, etirinotecan pegol, consists of irinotecan (a cancer medicine that belongs to the group ‘topoisomerase inhibitors') that has been ‘pegylated' (attached to a chemical called polyethylene glycol).
Estonian: Onzealdi toimeaine etirinotekaanpegool koosneb irinotekaanist (topoisomeraasi inhibiitorite rühma kuuluv vähiravim), mis on pegüleeritud (seotud keemilise ühendi polüetüleenglükooliga).
English: Because it is pegylated in etirinotecan pegol, the medicine is removed from the body at a slower rate, allowing the medicine to be given less often.
Estonian: Et irinotekaan on etirinotekaanpegoolis pegüleeritud, väljub ravim organismist aeglasemalt ja seda võib anda harvem.
English: What was Onzeald expected to be used for?
Estonian: Milleks kavatseti Onzealdi kasutada?
English: The CHMP considered that the benefit of Onzeald in the treatment of advanced breast cancer that had spread to the brain and other parts of the body had not been sufficiently demonstrated.
Estonian: Inimravimite komitee leidis, et Onzealdi kasulikkus peaajju ja organismis mujale levinud kaugelearenenud rinnavähi ravimisel ei olnud piisavalt tõendatud.
English: Onzeald was expected to be used to treat adults with advanced breast cancer that had spread to the brain and other parts of the body and who have already received other treatments.
Estonian: Onzealdi kavatseti kasutada peaajju ja organismis mujale levinud kaugelearenenud rinnavähi raviks täiskasvanutel, kes on juba saanud muud ravi.
English: It was to be available as a powder to be made into a solution for infusion (drip) into a vein.
Estonian: Seda kavatseti turustada veenisiseselt manustatava infusioonilahuse (veeni tilgutatava lahuse) pulbrina.
English: The mutual recognition procedure (UK/V/0354/001/MR) started on 26 November 2009.
Estonian: Vastastikuse tunnustamise menetlus (UK/V/0354/001/MR) algas 26. novembril 2009.
English: On 2 July 2010, the United Kingdom, as Reference Member State, referred the matter to the European Medicines Agency under Article 33(4) of Directive 2001/82/EC, due to concerns raised by the Concerned Member State, Ireland, that the safety and efficacy of the product had not been sufficiently demonstrated.
Estonian: 2. juulil 2010 tegi viiteliikmesriik Ühendkuningriik asjaomase liikmesriigi Iirimaa tõstatatud probleemi tõttu, et ravimi ohutus ja efektiivsus ei ole piisavalt tõendatud, Euroopa Ravimiametile direktiivi 2001/82/EÜ artikli 33 lõike 4 kohase esildise.
English: The marketing authorisation holder, Norbrook Laboratories Ltd, submitted an application for Combimox via a mutual recognition procedure in Ireland on the basis of the marketing authorisation granted by the United Kingdom.
Estonian: Müügiloa hoidja Norbrook Laboratories Ltd esitas Combimoxi Iirimaal vastastikuse tunnustamise menetluse taotluse Ühendkuningriigis antud müügiloa põhjal.
English: Combimox Lactating Cow Intramammary Suspension (Combimox) is an intramammary suspension containing amoxicillin, clavulanic acid and prednisolone.
Estonian: Lakteerivate veiste intramammaarsuspensioon Combimox (edaspidi Combimox) on intramammaarsuspensioon, mis sisaldab amoksitsilliini, klavulaanhapet ja prednisolooni.
English: The application was submitted as a generic of the reference product, Synulox Lactating Cow Intramammary Suspension marketed by Pfizer Ltd.
Estonian: Taotlus esitati Combimoxi kui geneerilise ravimi kohta; võrdlusravim on lakteerivate veiste intramammaarsuspensioon Synulox, mida turustab Pfizer Ltd.
English: Based on the evaluation of the rapporteur's assessment of the currently available data, the CVMP considered that the benefit/risk profile of Combimox Lactating Cow Intramammary Suspension is
Estonian: Tuginedes olemasolevatele andmetele ja hindaja hindamisaruandele, leidis veterinaarravimite komitee, et lakteerivate veiste intramammaarsuspensiooni Combimox kasulikkuse ja riski suhe on negatiivne.
English: Combimox is intended for the treatment of mastitis in lactating cows.
Estonian: Combimox on näidustatud mastiidi raviks lakteerivatel veistel.
English: Numient levodopa / carbidopa
Estonian: Numient levodopa/karbidopa
English: A risk management plan has been developed to ensure that Numient is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Numienti võimalikult ohutu kasutamine.
English: What measures are being taken to ensure the safe and effective use of Numient?
Estonian: Mis meetmed võetakse, et tagada Numienti ohutu ja efektiivne kasutamine?
English: The patient should then swallow the food immediately without chewing.
Estonian: Seejärel peab patsient toidu kohe närimata alla neelama.
English: The full EPAR and risk management plan summary for Numient can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Numienti kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Other information about Numient
Estonian: Muu teave Numienti kohta
English: Numient capsules are taken with a glass of water.
Estonian: Numienti kapsleid võetakse koos klaasitäie veega.
English: What is Numient and what is it used for?
Estonian: Mis on Numient ja milleks seda kasutatakse?
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that Numient's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Numienti kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Why is Numient approved?
Estonian: Miks Numient heaks kiideti?
English: The most frequent side effects with Numient are nausea in (12% of patients), dizziness, headache and involuntary movements (each occurring in 8% of patients), and insomnia (in 6% of patients).
Estonian: Numienti kõige sagedamad kõrvalnähud on iiveldus (12% patsientidest), pearinglus, peavalu ja tahtmatud liigutused (kõiki esines 8%-l patsientidest) ja unetus (6% patsientidest).
English: Patients who have difficulty swallowing can have the content of the capsules sprinkled on soft food such as apple sauce, yoghurt or pudding.
Estonian: Neelamisraskustega patsientidele võib kapslite sisu puistata pehme toidu, nt õunapüree, jogurti või pudingi peale.
English: Both groups had off periods of about 36-37% at the start of the study.
Estonian: Uuringu alguses oli off-seisundi protsentuaalne näit mõlemas rühmas ligikaudu 36-37%.
English: The starting dose for patients who have not previously taken levodopa is one capsule containing 95 mg of levodopa and 23.75 mg of carbidopa, three times daily for the first three days.
Estonian: Algannus patsientidele, kes ei ole varem levodopat võtnud, on üks 95 mg levodopat ja 23,75 mg karbidopat sisaldav kapsel kolm korda ööpäevas esimese kolme päeva jooksul.
English: 95 mg/23.75 mg, 145 mg/36.25 mg, 195 mg/48.75 mg and 245 mg/61.25 mg. For further information on how to use Numient, see the summary of product characteristic (also part of the EPAR).
Estonian: Numient on retseptiravim ja seda turustatakse järgmistes tugevustes: 95 mg/23,75 mg, 145 mg/36,25 mg, 195 mg/48,75 mg ja 245 mg/61,25 mg. Lisateave Numienti kasutamise kohta on ravimi omaduste kokkuvõttes (mis on samuti Euroopa avaliku hindamisaruande osa).
English: These types of capsules are known as modifiedrelease capsules.
Estonian: Selliseid kapsleid nimetatakse toimeainet modifitseeritult vabastavateks kapsliteks.
English: The doctor may then increase the dose depending on how the condition responds to treatment.
Estonian: Arst võib seejärel annust suurendada olenevalt ravivastusest.
English: After 30 weeks, patients taking Numient had their symptoms improve by an average of between 11.7 and 14.9 points (depending on dose) on a standard symptom scale (Unified Parkinson's Disease Rating Scale, UPDRS Part II and Part III).
Estonian: 30 nädala järel leevenesid Numienti saanud patsientide sümptomid keskmiselt 11,7-14,9 punkti (olenevalt annusest) sümptomite standardskaalal (ühtlustatud Parkinsoni tõve hindamisskaala, UPDRS, II ja III osa).
English: Patients who took placebo had an average improvement of 0.6 points.
Estonian: Platseebot saanud patsientide sümptomid leevenesid keskmiselt 0,6 punkti.
English: For patients already taking levodopa, the doctor will determine the dose of Numient based on their current treatment.
Estonian: Kui patsient juba võtab levodopat, määrab arst Numienti annuse tema praeguse ravi põhjal.
English: It is not intended to provide practical advice on how to use Numient.
Estonian: Hindamisaruandes ei anta Numienti kasutamise praktilisi nõuandeid.
English: What are the risks associated with Numient?
Estonian: Mis riskid Numientiga kaasnevad?
English: It must also not be used in patients taking medicines known as non-selective monoamine oxidase (MAO) inhibitors or in patients with a history of certain medical conditions.
Estonian: Samuti ei tohi seda kasutada mitteselektiivseid monoamiinoksüdaasi (MAO) inhibiitoreid võtvad patsiendid ega teatavate haiguste anamneesiga patsiendid.
English: They can be taken with or without food, but should not be taken at the same time as high protein meals, which can reduce absorption.
Estonian: Neid tohib võtta toiduga ja ilma, kuid mitte koos kõrge valgusisaldusega einetega, mis võib takistada ravimi imendumist.
English: The combination of levodopa and carbidopa is used in other medicines for Parkinson's disease.
Estonian: Levodopa ja karbidopa kombinatsiooni kasutatakse ka teistes Parkinsoni tõve ravimites.
English: Numient contains levodopa which converts into dopamine in the brain and helps to restore dopamine levels.
Estonian: Numient sisaldab levodopat, mis muundub ajus dopamiiniks ja aitab taastada dopamiini taseme.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Numient, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Numienti omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: In Numient, a portion of the active substances is released immediately, while the remaining is released gradually, leading to more steady levodopa levels.
Estonian: Osa Numienti toimeainetest vabaneb viivitamata ja ülejäänud järk-järgult, tagades ühtlase levodopa taseme.
English: After 13 weeks, patients taking Numient had off periods of about 24% of their waking hours compared with 30% of waking hours in patients taking the comparator medicine.
Estonian: 13 nädala järel esines Numienti võtnud patsientidel off-seisundit ärkvelolekuajast ligikaudu 24% ja võrdlusravimit võtnud patsientidel ligi 30%.
English: This is a summary of the European public assessment report (EPAR) for Numient.
Estonian: See on ravimi Numient Euroopa avaliku hindamisaruande kokkuvõte.
English: In a study of 381 patients with early stage Parkinson's disease, Numient at various doses was more effective at improving symptoms than placebo (a dummy treatment).
Estonian: Uuringus, milles osales 381 varajases staadiumis Parkinsoni tõvega patsienti, oli eri annustes manustatud Numient sümptomite leevendamisel efektiivsem kui platseebo (näiv ravim).
English: How is Numient used?
Estonian: Kuidas Numienti kasutatakse?
English: More serious side effects include bleeding from the gut and allergic reactions, and have been reported uncommonly.
Estonian: Tõsisemate kõrvalnähtude hulka kuuluvad aeg-ajalt esinevad sooleverejooks ja allergilised reaktsioonid.
English: Numient must not be used in patients with narrow angle glaucoma (an eye disorder) or pheochromocytoma (a tumour of the adrenal glands).
Estonian: Numienti ei tohi kasutada kitsa nurga glaukoomiga (silmakahjustus) ega feokromotsütoomiga (neerupealiste kasvaja) patsiendid.
English: For practical information about using Numient, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Numienti kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: This study looked at how well the treatments reduced the time when patients have more difficulty moving about, called ‘off periods'.
Estonian: Selles uuringus vaadeldi, kui palju vähendasid ravimid patsientidel liikumisraskuste (off-seisundi) kestust.
English: Another benefit is the way the active substances are formulated in Numient, which helps maintain more steady levodopa levels.
Estonian: Kasulik on ka Numienti toimeainesisaldus, mis aitab säilitada ühtlasemat levodopa taset.
English: Studies show that Numient is effective at reducing symptoms in patients with early and late stage Parkinson's disease.
Estonian: Uuringute kohaselt on Numient efektiivne varajases ja hilises staadiumis Parkinsoni tõvega patsientide sümptomite vähendamisel.
English: A second study compared Numient with another treatment containing levodopa and carbidopa in 393 patients with advanced Parkinson's disease.
Estonian: Teises uuringus võrreldi Numienti teise levodopat ja karbidopat sisaldava ravimiga 393 kaugelearenenud Parkinsoni tõvega patsiendil.
English: What benefits of Numient have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Numienti kasulikkus?
English: For more information about treatment with Numient, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Numientiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: In patients with Parkinson's disease, the cells in the brain that produce dopamine, a neurotransmitter important for controlling movement, begin to die and the amount of dopamine in the brain decreases.
Estonian: Parkinsoni tõvega patsiendil hakkavad liigutuste juhtimiseks vajalikku neurotransmitterit dopamiini tootvad ajurakud hävima ja dopamiini hulk ajus väheneb.
English: The carbidopa in Numient stops the levodopa from converting into dopamine while still in the general circulation, before it has reached the brain.
Estonian: Numientis sisalduv karbidopa hoiab ära levodopa muundumise dopamiiniks üldvereringes enne ajju jõudmist.
English: How does Numient work?
Estonian: Kuidas Numient toimib?
English: It contains the active substances levodopa and carbidopa.
Estonian: Numient sisaldab toimeainetena levodopat ja karbidopat.
English: Numient is available as capsules to be taken by mouth.
Estonian: Numienti turustatakse suukaudsete kapslitena.
English: Numient is used in adults to treat the symptoms of Parkinson's disease, a progressive brain disorder that causes shaking and muscular stiffness and slows down movement.
Estonian: Parkinsoni tõbi on progresseeruv ajuhäire, mis põhjustab värinaid, liigutuste aeglust ja lihasjäikust.
English: ATCvet code: QI08AA
Estonian: ATCvet kood: QI08AA
English: The active substance being a principle of biological origin intended to produce active immunity is not within the scope of Regulation (EC) No 470/2009.
Estonian: Toimeained kui aktiivse immuniseerimise esilekutsumiseks ette nähtud bioloogilist päritolu ained ei kuulu määruse (EÜ) 470/2009 reguleerimisalasse.
English: {MM/YYYY}
Estonian: {kk/aaaa}
English: If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.
Estonian: Kui täheldate ükskõik milliseid kõrvaltoimeid, isegi neid, mida pole käesolevas pakendi infolehes mainitud, või arvate, et ravim pole toiminud, teavitage palun sellest oma veterinaararsti.
English: Date of first authorisation: 22 September 2016
Estonian: Esmase müügiloa väljastamise kuupäev: 22.09.2016
English: Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP.
Estonian: Ärge kasutage seda ravimit pärast kõlblikkusaega, mis on märgitud etiketil pärast EXP.
English: A transient temperature increase slightly above 40 ºC might very commonly occur between two or three days following vaccination.
Estonian: Temperatuuri mööduv tõus veidi üle 40 ºC võib väga sageli ilmneda kahe või kolme päeva jooksul pärast vaktsineerimist.
English: These local reactions gradually reduce and disappear without need for treatment.
Estonian: Need paiksed reaktsioonid aegamisi vähenevad ja kaovad ilma ravita.
English: Detailed information on this product is available on the website of the European Medicines Agency http://www.ema.europa.eu
Estonian: Üksikasjalikku teavet antud veterinaarravimi kohta leiab Euroopa Ravimiameti koduleheküljelt http://www.ema.europa.eu/.
English: Mineral oil
Estonian: Mineraalõli
English: Vaccinate healthy animals only.
Estonian: Vaktsineerige ainult terveid loomi.
English: If pain persists for more than 12hours after medical examination, seek medical advice again.
Estonian: Juhul kui valu püsib rohkem kui 12 tundi pärast arstlikku kontrolli, pöörduda uuesti arsti poole.
English: No available data.
Estonian: Andmed puuduvad.
English: Onset of immunity: 1 week.
Estonian: Aeg immuunsuse tekkeni: 1 nädal.
English: The vaccine provides protection only against RHDV2, cross protection against classical RHDV has not been demonstrated.
Estonian: Vaktsiin kaitseb ainult RHDV2 vastu, ristkaitset klassikalise RHDV vastu ei ole täheldatud.
English: Each dose of 0.5 ml contains:
Estonian: Üks 0,5 ml annus sisaldab:
English: Sorbitan mono-oleate Polysorbate 80
Estonian: Sorbitaanmonooleaat Polüsorbaat 80